Lupin share news, announcements and annual reports
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Lupin Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1993 on BSE, Sep 2001 on NSE
Last close ₹2,011.00up ₹21.10 (1.06%)BSE ₹2,009.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,989.90.
30 Oct: open ₹1,995.70, high ₹2,021.80, low ₹1,974.00
52-week range of traded prices to 30 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹91,961 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.63
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 15.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,59,66358.6% delivered
Lupin board and management
34 filed, newest first.
Oct 2026
22 Oct · Management
May 2026
7 May · Management
Jan 2026
6 Jan · Management
Aug 2025
20 Aug · Management
11 Aug · Management
May 2025
20 May · Management
Feb 2025
12 Feb · Management
Oct 2024
18 Oct · Management
Jun 2024
May 2024
Apr 2024
3 Apr · Management
Mar 2024
Dec 2022
Oct 2022
May 2021
10 May · Management
Jan 2021
Nov 2020
Aug 2020
Mar 2020
Jun 2019
Mar 2019
Dec 2018
Nov 2018
Aug 2017
Sep 2012
28 Sep · Management
Dr. Kamal K. Sharma has been re-appointed for a period of three years effective September 29, 2012 as the Managing Director of the Company or other mutually agreed capacity subject to the approval of the shareholders.
Nov 2011
9 Nov · Management
Mr. K. V. Kamath, resigned from the directorship of the Company w.e.f. November 09, 2011.
Nov 2010
1 Nov · Management
Board of Directors of the Company at their meeting held on November 01, 2010, the Board has:-(1) Re-appointed Dr. Desh Bandhu Gupta as Executive Chairman and Mrs. M. D. Gupta as Executive Director of the Company, for a period of five years w.e.f. January 01, 2011. The same shall be subject to approval of the shareholders.
May 2010
5 May · Management
At the meeting of the Board of Directors held on May 05, 2010, has noted the resignation of Mr. Sunil Nair from the directorship of the Company w.e.f. May 05, 2010.
Jan 2010
29 Jan · Management
At the meeting of the Board of Directors held on January 29, 2010 , the Board has : (1) Approved Dr. Vijay Kelkar, Mr. K. V. Kamath and Mr. Richard Zahn as Additional Directors; (2) The resignation of Mr. Marc Desaedeleer from the Directorship of the Company.
Oct 2008
8 Oct · Management
At the meeting of the Board of Directors held on October 08, 2008, the following decisions were taken: a) Dr. Kamal K. Sharma was re-appointed as Managing Director of the Company for a period of four years w.e.f. September 29, 2008. 2) Mr. Nilesh Gupta was appointed as Additional Director of the Company w.e.f. October 08, 2008 and is designated, Executive Director.
Apr 2008
30 Apr · Management
Mr. Kiran N. Bade, Company Secretary & Compliance Officer, has resigned from the services of the Company w.e.f. May 01, 2008 and Mr. R.V. Satam has been appointed in his place
Jan 2008
22 Jan · Management
Dr. Vijay Kelkar has ceased to be a Director of the Company w.e.f. December 31, 2007. The President of India has constituted the Finance Commission under the Chairmanship of Dr. Kelkar, who has assumed its charge on January 1, 2008. Considering the nature of his office, Dr. Kelkar has decided to withdraw from all his Directorships